The Clinical Potential of Oligonucleotide Therapeutics against Pancreatic Cancer
Open Access
- 6 July 2019
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 20 (13) , 3331
Abstract
Although many diagnostic and therapeutic modalities for pancreatic cancer have been proposed, an urgent need for improved therapeutic strategies remains. Oligonucleotide therapeutics, such as those based on antisense RNAs, small interfering RNA (siRNA), microRNA (miRNA), aptamers, and decoys, are promising agents against pancreatic cancer, because they can identify a specific mRNA fragment of a given sequence or protein, and interfere with gene expression as molecular-targeted agents. Within the past 25 years, the diversity and feasibility of these drugs as diagnostic or therapeutic tools have dramatically increased. Several clinical and preclinical studies of oligonucleotides have been conducted for patients with pancreatic cancer. To support the discovery of effective diagnostic or therapeutic options using oligonucleotide-based strategies, in the absence of satisfactory therapies for long-term survival and the increasing trend of diseases, we summarize the current clinical trials of oligonucleotide therapeutics for pancreatic cancer patients, with underlying preclinical and scientific data, and focus on the possibility of oligonucleotides for targeting pancreatic cancer in clinical implications.Keywords
All Related Versions
This publication has 121 references indexed in Scilit:
- Emerging concepts in pancreatic cancer medicine: targeting the tumor stromaOncoTargets and Therapy, 2013
- MAZ-binding G4-decoy with locked nucleic acid and twisted intercalating nucleic acid modifications suppresses KRAS in pancreatic cancer cells and delays tumor growth in miceNucleic Acids Research, 2013
- Comparing human pancreatic cell secretomes by in vitro aptamer selection identifies cyclophilin B as a candidate pancreatic cancer biomarkerJournal of Clinical Investigation, 2012
- OGX-427 inhibits tumor progression and enhances gemcitabine chemotherapy in pancreatic cancerCell Death & Disease, 2011
- A Gene Expression Signature Associated with “K-Ras Addiction” Reveals Regulators of EMT and Tumor Cell SurvivalCancer Cell, 2009
- The Chemical Biology of AptamersAngewandte Chemie International Edition, 2009
- TGFβ in CancerCell, 2008
- HMGA1 Is a Molecular Determinant of Chemoresistance to Gemcitabine in Pancreatic AdenocarcinomaClinical Cancer Research, 2008
- Strategies for silencing human disease using RNA interferenceNature Reviews Genetics, 2007
- Targeted tumor therapy with the TGF-β2 antisense compound AP 12009Cytokine & Growth Factor Reviews, 2006